Antigen-specific therapies, CD22 targeting, CAR-T cell approaches, and combination therapies are paving the way for more precise and effective treatments that may transform the management of autoimmune diseases like T1D. This evidence concerns the gene CD22 and type 1 diabetes mellitus.